^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PMR-116

    i
    Other names: PMR-116, PMR116, PMR 116
    Associations

    News

    Trials
    Company:
    Pimera Therap
    Drug class:
    RNA polymerase 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    A Phase I study of PMR-116 in Patients with Advanced Malignancies (ACTRN12620001146987)
    P1, N=54, Terminated, Pimera Australia Pty Ltd | Recruiting --> Terminated
    Trial termination • Metastases
    |
    MYC positive
    |
    PMR-116
    almost2years
    RNA Polymerase I inhibitors for cancer therapy (LCC 2023)
    To address the need for improved Pol I inhibitors with minimal off-target effects we collaborated with Pimera Inc to develop a selective 2nd-generation Pol I inhibitor, PMR-116. We show that combinatorial therapy with CX-5461 and both Flavopiridol and Dinaciclib have a synergistic effect in vitro and significantly increase the survival of acute myeloid leukaemia (AML) models in vivo. Our data indicates that inhibition of both Pol I (by CX-5461) and Pol II (by CDK9 inhibitors) can be used in as a therapy to extend survival and reduce acquired resistance.
    BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    pidnarulex (CX-5461) • alvocidib (DSP-2033) • dinaciclib (MK-7965) • PMR-116
    almost3years
    PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer (AACR 2022)
    PMR-116 treatment decreased tumour volume in all PDX tested including complete response in a line in which tumour volume decreased by ~90% compared to baseline.We believe this new RNA Pol I inhibitor shows promising results in a wide range of preclinical models and may exert higher efficacy in tumours expressing high levels of MYC. PMR-116 is currently in Phase I dose escalation trial in patient with solid tumours (ACTRN12620001146987).
    Preclinical
    |
    PTEN (Phosphatase and tensin homolog) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
    |
    MYC expression
    |
    PMR-116